MedPath

Comparison of two ways of using medications for preventing graft versus host disease after a half-matched stem cell transplant

Phase 2
Conditions
Health Condition 1: C920- Acute myeloblastic leukemia
Registration Number
CTRI/2024/06/068451
Lead Sponsor
Indian Council of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients planned for haploidentical stem cell transplantation using post-transplant cyclophosphamide

Exclusion Criteria

1. Patients planned for T cell depleted haplodentical stem cell transplantation

2. Patients with significant organ dysfunction (creatinine above 2mg%, liver enzymes above 5 times the upper limit of normal, LV ejection fraction less than 40%)

3. Patients with active infection at the time of transplant

4. Patients undergoing a second transplant

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath